

THIS IS A DRAFT PAPER DEVELOPED FOR THE NATIONAL BIOETHICS ADVISORY COMMISSION. IT DOES NOT REPRESENT CONCLUSIONS AND SHOULD NOT BE CITED OR REFERENCED.-- DECEMBER 29, 1997

#### **IV. Framework for Analysis**

---

*[to be written after full Commission discussion]*

This chapter will describe the framework used by the Commission to help it formulate recommendations. This includes consideration of the distinctions between the collection of tissue samples in routine clinical care versus research, previously collected samples versus those to be collected in the future, anonymized versus identifiable tissues, the consent process, the role of Institutional Review Boards, the appropriateness of community consultation, and measures to ensure confidentiality and restricted access to tissue samples. (See tables.)

#### **Tissue Samples Collected in Clinical Care or with No Known Research vs. Research Studies**

#### **Distinction Between Previously Collected Samples and Samples Collected in the Future**

#### **Distinctions Between Anonymized versus Identifiable Tissues**

#### **Informed Consent and Disclosure**

Federal consent requirements for medical treatment and human research

Physician/patient and researcher/subject relationships

Necessary components of informed consent

Scope of consent

- description of intended use of samples
- anonymized/identifiable
- identifiable harms
- possible research/clinical outcomes (therapeutic expectations)
- access to tissues
- duration and storage of tissues
- fully informed, general informed, implied, opt out
- freedom to withdraw from research

THIS IS A DRAFT PAPER DEVELOPED FOR THE NATIONAL BIOETHICS ADVISORY COMMISSION. IT DOES NOT REPRESENT CONCLUSIONS AND SHOULD NOT BE CITED OR REFERENCED.-- DECEMBER 29, 1997

recontact - NHANES/CDC example

Disclosure in the research setting

HIV example - OPRR mandate that all research subjects tested for HIV infection must be informed of their results if the result can be linked to the subject.

Community consultation

## **The Role of Institutional Review Boards**

### **Provision of Confidentiality and Privacy**

general issues concerning medical records

DHHS report on "Confidentiality of Individually-Identifiable Health Information"

identifiability/security issues

"Two-way" track

"One-way" track

### **Research Using Previously Collected Samples**

**(boxes 1A,1B,2A,2B,3A,3B)**

(discuss why purpose at time of sample collection is not an issue)

- to be used in an anonymous manner vs. to be used so identification is possible
- individual vs. community
- no potential harms versus potential harms

### **Research Using Samples Collected in the Future**

**(boxes 1C,1D,1E,1F,2C,2D,2E,2F,3C,3D,3E,3F)**

- purpose at time of collection (clinical care or no known research vs. research) vs. to be used so identification is possible
- individual vs. community

THIS IS A DRAFT PAPER DEVELOPED FOR THE NATIONAL BIOETHICS ADVISORY COMMISSION. IT DOES NOT REPRESENT CONCLUSIONS AND SHOULD NOT BE CITED OR REFERENCED.-- DECEMBER 29, 1997

- no potential harms versus potential harms